دورية أكاديمية
Memory B Cells and Response to Abatacept in Rheumatoid Arthritis.
| العنوان: | Memory B Cells and Response to Abatacept in Rheumatoid Arthritis. |
|---|---|
| المؤلفون: | Gazeau P; Laboratory of Immunology and Immunotherapy, CHU Morvan, Brest, France.; Unit of Rheumatology, CHRU Brest-Carhaix, Hôpital Cavale Blanche, Brest, France., Alegria GC; Laboratory of Immunology and Immunotherapy, CHU Morvan, Brest, France.; Unit of Rheumatology, CHRU Brest-Carhaix, Hôpital Cavale Blanche, Brest, France., Devauchelle-Pensec V; Unit of Rheumatology, CHRU Brest-Carhaix, Hôpital Cavale Blanche, Brest, France.; INSERM U1227, LabEx IGO 'Immunotherapy Graft Oncolog', Réseau épigénétique et réseau canaux ioniques du Cancéropole Grand Ouest, European University of Brittany, Brest, France., Jamin C; Laboratory of Immunology and Immunotherapy, CHU Morvan, Brest, France.; INSERM U1227, LabEx IGO 'Immunotherapy Graft Oncolog', Réseau épigénétique et réseau canaux ioniques du Cancéropole Grand Ouest, European University of Brittany, Brest, France., Lemerle J; Laboratory of Immunology and Immunotherapy, CHU Morvan, Brest, France., Bendaoud B; Laboratory of Immunology and Immunotherapy, CHU Morvan, Brest, France.; INSERM U1227, LabEx IGO 'Immunotherapy Graft Oncolog', Réseau épigénétique et réseau canaux ioniques du Cancéropole Grand Ouest, European University of Brittany, Brest, France., Brooks WH; Department of Chemistry, University of South Florida, Tampa, FL, USA., Saraux A; Unit of Rheumatology, CHRU Brest-Carhaix, Hôpital Cavale Blanche, Brest, France.; INSERM U1227, LabEx IGO 'Immunotherapy Graft Oncolog', Réseau épigénétique et réseau canaux ioniques du Cancéropole Grand Ouest, European University of Brittany, Brest, France., Cornec D; Unit of Rheumatology, CHRU Brest-Carhaix, Hôpital Cavale Blanche, Brest, France.; INSERM U1227, LabEx IGO 'Immunotherapy Graft Oncolog', Réseau épigénétique et réseau canaux ioniques du Cancéropole Grand Ouest, European University of Brittany, Brest, France., Renaudineau Y; Laboratory of Immunology and Immunotherapy, CHU Morvan, Brest, France. yves.renaudineau@univ-brest.fr.; INSERM U1227, LabEx IGO 'Immunotherapy Graft Oncolog', Réseau épigénétique et réseau canaux ioniques du Cancéropole Grand Ouest, European University of Brittany, Brest, France. yves.renaudineau@univ-brest.fr. |
| المصدر: | Clinical reviews in allergy & immunology [Clin Rev Allergy Immunol] 2017 Oct; Vol. 53 (2), pp. 166-176. |
| نوع المنشور: | Journal Article |
| اللغة: | English |
| بيانات الدورية: | Publisher: Humana Press Country of Publication: United States NLM ID: 9504368 Publication Model: Print Cited Medium: Internet ISSN: 1559-0267 (Electronic) Linking ISSN: 10800549 NLM ISO Abbreviation: Clin Rev Allergy Immunol Subsets: MEDLINE |
| أسماء مطبوعة: | Original Publication: Totowa, NJ : Humana Press, c1995- |
| مواضيع طبية MeSH: | Abatacept/*therapeutic use , Arthritis, Rheumatoid/*drug therapy , B-Lymphocyte Subsets/*immunology , B-Lymphocytes/*immunology , T-Lymphocytes/*immunology, Adult ; Aged ; Arthritis, Rheumatoid/immunology ; CTLA-4 Antigen/antagonists & inhibitors ; Female ; Humans ; Immunologic Memory ; Lymphocyte Activation ; Lymphocyte Count ; Male ; Middle Aged ; Retrospective Studies ; Treatment Outcome |
| مستخلص: | Abatacept is a fusion protein (CTLA4-Ig) and therapeutic molecule labeled for the treatment of rheumatoid arthritis (RA). Abatacept acts both by disrupting the CD28-mediated activation of T cells and by interacting with CD80/CD86 molecules present on antigen presenting cells such as monocytes and memory B cells. Accordingly and to evaluate clinical and biological parameters associated with response to abatacept, a retrospective monocentric study was conducted in 43 patients with RA, and the clinical response was evaluated at 6 months according to EULAR response criteria. Median age of the patients was 59.8 ± 15.1 years including 35 females and 8 males. At baseline, no difference was observed between non-responders (NR, n = 11), moderate responders (MR, n = 21), and good responders (GR, n = 11) to abatacept with regards to demographic, biological, and clinical characteristics of the patients (age, sex, anti-CCP, RF, FcγR3A V158F polymorphism, and C3/C4 complement reduction). Moreover, peripheral blood lymphocyte phenotyping was performed by flow cytometry revealing in 30 RA patients compared to controls (n = 45; median age 56.7 ± 13.5 years) that the initial CD19 + B cell count was reduced in NR and MR but not in GR. No differences were observed with regards to total lymphocyte, T cell, and NK cell counts. Next, we further explored the effects of abatacept on B cell subsets (IgD/CD38 in panel 1 and IgD/CD27 in panel 2) and observed that the basal level of CD38 + and/or CD27 + memory B cell count was important for an abatacept response and that a selective effect of abatacept was observed on memory B cells after 6 months. In conclusion, and although these data need to be confirmed in an independent cohort, our data support a role for memory B cells in the mechanism of action of abatacept in RA. |
| References: | Clin Rev Allergy Immunol. 2017 May 4;:null. (PMID: 28474288) Autoimmunity. 2005 Feb;38(1):11-6. (PMID: 15804700) Arthritis Rheum. 2006 Aug;54(8):2523-32. (PMID: 16868973) Arthritis Res Ther. 2010;12(2):R68. (PMID: 20398308) PLoS One. 2015 Jun 05;10(6):e0128269. (PMID: 26047509) Autoimmun Rev. 2006 Mar;5(3):215-21. (PMID: 16483922) Autoimmun Rev. 2010 Jul;9(9):627-30. (PMID: 20452464) J Immunol. 2009 May 1;182(9):5623-32. (PMID: 19380809) Ann Rheum Dis. 2008 Nov;67(11):1603-9. (PMID: 18203760) J Autoimmun. 2013 Mar;41:175-81. (PMID: 23478041) J Allergy Clin Immunol. 2016 Jan;137(1):28-34. (PMID: 26768760) Clin Exp Rheumatol. 2005 Sep-Oct;23(5 Suppl 39):S93-9. (PMID: 16273792) J Allergy Clin Immunol. 2016 Jan;137(1):19-27. (PMID: 26768759) Immunotherapy. 2016 May;8(5):569-81. (PMID: 27140410) J Autoimmun. 2015 Jul;61:54-61. (PMID: 26071203) Arthritis Res Ther. 2015 Mar 14;17 :61. (PMID: 25888920) J Autoimmun. 2013 Feb;40:74-85. (PMID: 22980031) Clin Rev Allergy Immunol. 2017 May 30;:null. (PMID: 28560621) Front Microbiol. 2016 Aug 17;7:1296. (PMID: 27582741) Rheumatology (Oxford). 2016 Jun;55(6):1138-40. (PMID: 26667217) Arthritis Rheum. 1994 Nov;37(11):1637-46. (PMID: 7526869) Front Immunol. 2015 Aug 26;6:437. (PMID: 26379672) Arthritis Rheum. 2013 Mar;65(3):599-607. (PMID: 23203906) Autoimmun Rev. 2004 Nov;3(7-8):516-23. (PMID: 15546800) Oncoimmunology. 2016 Mar 16;5(5):e1132977. (PMID: 27467951) J Immunol. 2007 Oct 15;179(8):5109-16. (PMID: 17911596) Arthritis Rheum. 2009 Jul;60(7):1873-80. (PMID: 19565509) Ann N Y Acad Sci. 2005 Jun;1050:170-5. (PMID: 16014531) J Autoimmun. 2014 May;50:67-76. (PMID: 24365380) Autoimmun Rev. 2013 Oct;12(12):1171-6. (PMID: 23851140) Arthritis Rheum. 2007 May;56(5):1464-77. (PMID: 17469105) Rheumatology (Oxford). 2008 Apr;47(4):514-8. (PMID: 18321947) Nat Rev Rheumatol. 2010 Aug;6(8):468-76. (PMID: 20567251) Eur J Haematol. 2016 Mar;96(3):229-35. (PMID: 25911969) J Immunol. 2001 Oct 1;167(7):3610-8. (PMID: 11564773) Arthritis Rheum. 2010 Sep;62(9):2569-81. (PMID: 20872595) Autoimmun Rev. 2014 Nov;13(11):1102-8. (PMID: 25172238) Arthritis Res Ther. 2014 Apr 15;16(2):R95. (PMID: 24735586) Joint Bone Spine. 2009 Oct;76(5):458-63. (PMID: 19640767) Ann Rheum Dis. 2009 Jun;68(6):954-60. (PMID: 18490431) J Autoimmun. 2010 May;34(3):J207-19. (PMID: 20053532) Autoimmun Rev. 2013 Oct;12(12):1115-7. (PMID: 23800448) J Rheumatol. 2007 Nov;34(11):2204-10. (PMID: 17787038) Arthritis Res Ther. 2009;11(3):R62. (PMID: 19419560) Clin Rev Allergy Immunol. 2017 May 9;:null. (PMID: 28488248) Arthritis Rheum. 2004 Jun;50(6):1918-27. (PMID: 15188368) J Autoimmun. 2010 Dec;35(4):336-41. (PMID: 20810246) Arthritis Res Ther. 2014 Jan 17;16(1):R15. (PMID: 24433480) Autoimmun Rev. 2014 Nov;13(11):1109-13. (PMID: 25172240) Arthritis Rheum. 1998 Oct;41(10):1845-50. (PMID: 9778226) Kidney Int. 2014 Mar;85(3):590-9. (PMID: 24284517) Blood. 2011 Aug 25;118(8):2150-8. (PMID: 21690558) Arthritis Rheum. 1988 Mar;31(3):315-24. (PMID: 3358796) Autoimmun Rev. 2014 Nov;13(11):1114-20. (PMID: 25182207) Arthritis Rheum. 2011 Dec;63(12):3692-701. (PMID: 22127692) Arthritis Rheum. 2002 Jun;46(6):1470-9. (PMID: 12115176) J Autoimmun. 2014 Feb-Mar;48-49:26-30. (PMID: 24568777) J Autoimmun. 2012 Sep;39(3):154-60. (PMID: 22709855) Ann Rheum Dis. 2012 Jun;71(6):862-8. (PMID: 22267329) Clin Rev Allergy Immunol. 2017 Apr 29;:null. (PMID: 28456914) Scand J Rheumatol. 2012 May;41(3):180-5. (PMID: 22400711) J Autoimmun. 2015 Feb;57:60-5. (PMID: 25556904) Ann Hematol. 2012 May;91(5):715-721. (PMID: 22083514) Autoimmun Rev. 2015 Oct;14(10):854-63. (PMID: 26026695) Autoimmun Rev. 2016 May;15(5):447-50. (PMID: 26808074) Arthritis Res Ther. 2010;12(3):R108. (PMID: 20525218) Clin Kidney J. 2013 Feb;6(1):74-76. (PMID: 27818754) J Autoimmun. 2015 Dec;65:1-18. (PMID: 26515757) Arthritis Rheum. 2007 Mar 15;57(2):310-7. (PMID: 17330280) |
| فهرسة مساهمة: | Keywords: Abatacept; Memory B cells; Rheumatoid arthritis; Therapeutic response |
| المشرفين على المادة: | 0 (CTLA-4 Antigen) 7D0YB67S97 (Abatacept) |
| تواريخ الأحداث: | Date Created: 20170507 Date Completed: 20180705 Latest Revision: 20181113 |
| رمز التحديث: | 20221213 |
| DOI: | 10.1007/s12016-017-8603-x |
| PMID: | 28477078 |
| قاعدة البيانات: | MEDLINE |
Find this article in full text from Springer Verlag. 
Full Text Finder | تدمد: | 1559-0267 |
|---|---|
| DOI: | 10.1007/s12016-017-8603-x |